Pharmacy Lien Free Choice: What Client Autonomy Requires

James Wong — Founder & Pharmacist, LienScripts | November 18, 2025 | 8 min read

Recommending a pharmacy lien provider that limits where your client fills prescriptions raises real RPC concerns. Here's what client autonomy requires.

The Client Autonomy Principle Under Model Rule 1.2

When a client retains a personal injury attorney, they hand over significant decision-making authority. They trust their attorney to evaluate liability, negotiate with insurers, and manage the litigation strategy. But under ABA Model Rule 1.2, that deference has a hard limit: the client always controls the objectives of the representation.

That principle extends beyond case strategy. When an attorney recommends a specific pharmacy lien provider — effectively channeling where a client fills prescriptions and how their lien is structured — the nature of that provider arrangement matters. Not all pharmacy lien programs are built the same way, and the differences have real ethics implications.

[!KEY] Recommending a provider that locks a client into a single pharmacy or restricts where they can fill prescriptions is structurally different from recommending an open-access service. The first limits client autonomy. The second preserves it.

What "Captive" Pharmacy Arrangements Look Like

Not every pharmacy lien program operates the same way. Some are structured around a proprietary card that only works at specific pharmacies or pharmacy networks. Others tie the pharmacy service to a lien purchasing entity — meaning the company that issues the card also profits from acquiring and holding the lien.

These arrangements raise two questions that every PI attorney should ask before referring a client:

Question 1: Can my client use their regular pharmacist? If the answer is no — if the program requires clients to use a specific pharmacy, chain, or mail-order service controlled by the lien provider — that's a constraint on client freedom of choice. Some clients have longstanding relationships with local pharmacists, especially elderly patients, patients with complex medication regimens, or patients in rural areas where a specific pharmacy is their only practical option.

Question 2: Is the entity issuing the card the same entity that purchases the lien? When a company both originates the pharmacy relationship and profits from acquiring the resulting lien, its financial incentives may not align with the client's interest in keeping the lien amount reasonable. The lien purchaser profits from a higher lien amount; the client profits from a lower one.

[!WARNING] If the answer to either question is yes, that arrangement warrants additional scrutiny — and likely explicit disclosure to your client before enrollment.

True Free Choice in Practice: What It Actually Means

A pharmacy lien arrangement that genuinely preserves client autonomy has two characteristics.

First, the client can fill prescriptions anywhere — their neighborhood pharmacy, a national chain like CVS or Walgreens, a local independent, or through home delivery via mail order. The lien is not tied to a specific dispensing location. The patient's access to medication doesn't depend on their willingness to use a particular pharmacy.

Second, there's a functional backup for situations where the primary delivery method doesn't apply. Mail order, for example, is the most convenient default for most injured patients — medications arrive at their door, which matters when a client can't drive due to their injuries. But controlled substances often cannot be delivered by mail under DEA regulations, so a pharmacy card provides access when a patient needs to fill a Schedule II prescription at a local pharmacy or is traveling.

The distinction between a card-first model and a mail-order-primary model is significant. A card-first model requires the patient to go to a pharmacy that accepts the card. A mail-order-primary model assumes the patient can't easily travel and solves that problem first — the card is a supplement, not the access point.

[!KEY] Free choice isn't just a marketing phrase — it's what Model Rule 1.2 implies when a client has a preferred pharmacist, limited mobility, or needs continuity of care with a provider they already trust.

Conflict of Interest Analysis: Rules 1.7 and 1.8

The conflict of interest analysis under ABA Model Rule 1.7 and Rule 1.8(e) is fact-specific, but the framework is clear: attorneys cannot have financial interests that materially limit their ability to represent a client.

When a pharmacy lien provider pays referral fees, shares revenue, or has any financial arrangement with the referring attorney, Rule 1.8(e) is directly implicated. Most legitimate pharmacy lien programs don't involve attorney compensation — they're referred because they solve a client problem, not because the attorney benefits financially.

But the more nuanced issue is the structure of the lien provider itself. When a single entity both runs the pharmacy program and purchases the resulting lien, that entity has a financial incentive to maximize the lien amount. The attorney who referred the client to that entity should ask: am I recommending this provider because it serves my client's interests, or because it's convenient?

[!NOTE] Most state bars have not issued formal opinions specifically addressing pharmacy lien referral arrangements. That absence doesn't mean the arrangement is unregulated — it means the general conflict of interest and client autonomy rules apply, and attorneys are expected to analyze them.

What to Disclose to Clients Before Enrollment

Even when a pharmacy lien arrangement is structurally sound, clients should understand what they're agreeing to. The basics of informed consent in this context are covered in detail in our guide on pharmacy lien client disclosure and informed consent, but for purposes of the free choice question, three specific disclosures matter:

1. Client can use any pharmacy. If your provider genuinely offers open access, say so explicitly. "You can fill your prescriptions at any pharmacy, or we can arrange home delivery" is a one-sentence disclosure that removes ambiguity.

2. The lien provider does not purchase the lien. Confirm that the entity providing the pharmacy service is a pharmacy company, not a medical lien purchaser. These are different business models with different incentive structures.

3. Client can opt out. If a client has a preferred pharmacy or doesn't want to use the recommended provider, they should be able to say so without losing access to their medications. A pharmacy lien program that cannot accommodate client preference on something as basic as pharmacy choice is not preserving client autonomy — it's constraining it.

[!TIP] Add a single sentence to your intake documentation: "We work with a pharmacy lien provider that offers home delivery and a pharmacy card — you can use any pharmacy you prefer." That disclosure is simple, accurate, and documents your compliance with client autonomy requirements.

The Attorney Ethics Checklist: 5 Questions Before Choosing a Provider

Before recommending any pharmacy lien provider to your clients, run through this checklist:

1. Can my client use their existing pharmacist or any pharmacy of their choice? If the answer is no, or if the program is limited to a specific network, that's a constraint on client autonomy that requires disclosure — or reconsideration of the referral.

2. Does this provider hold or purchase pharmacy liens? A company that both originates and purchases liens has a different financial incentive structure than a pure pharmacy service provider. Understand which category your provider falls into.

3. Is there any financial incentive for this provider to increase the lien amount? Lien purchasers profit from higher lien values. Pure pharmacy providers do not. The distinction matters for whose interests are being optimized.

4. Does the provider have licensed clinical staff reviewing prescriptions? This is a patient safety question as much as an ethics one. A provider with PharmD-level clinical oversight can flag drug interactions, navigate prior authorization, and support the clinical narrative in your case. A card processor cannot.

5. Can the client opt out of this provider if they choose a different pharmacy? The answer should be yes, with a clear process for doing so that doesn't leave the client without medication access.

[!KEY] A pharmacy lien provider that passes all five checks is structurally different from one that doesn't — and that difference is worth understanding before you make the referral.

Why This Question Is Getting More Attention

As pharmacy lien programs have expanded nationally, state bar ethics committees and plaintiff attorneys have started asking harder questions about the structure of these arrangements. The legal industry is becoming more sophisticated about distinguishing between programs that genuinely serve clients and programs that use clients as the revenue mechanism.

PI attorneys who have thought carefully about these questions — and who can articulate why their recommended provider preserves client autonomy — are in a stronger position when those questions get asked by a client, a referral partner, or a state bar inquiry.

The goal isn't to avoid pharmacy lien programs. They solve a real problem: injured clients need medications, and most can't pay out of pocket during litigation. The goal is to use the right kind of program — one where the pharmacy and the lien are structurally aligned with the client's interests, not the provider's.

For further reading on the California-specific RPC analysis, see our post on California RPC obligations for pharmacy lien attorneys. For the specific disclosure language, see pharmacy lien client disclosure and informed consent.

[!SOURCE] ABA Model Rule 1.2 — Scope of Representation and Allocation of Authority Between Client and Lawyer — Establishes the client's right to control the objectives of representation.

[!SOURCE] ABA Model Rule 1.8 — Conflict of Interest: Current Clients: Specific Rules — Governs financial assistance to clients in litigation and attorney conflicts arising from third-party arrangements.